Hydromorphone Syringe Recalled Due to Lack of Sterility Assurance
Central Admixture Pharmacy Services Inc. is recalling hydromorphone syringes due to lack of assurance of sterility. The recall affects 274 syringes distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses, injuries, or deaths. The hazard is a quality assurance issue (lack of sterility assurance) without confirmed contamination or reported harm, meeting the criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Central Admixture Pharmacy Services Inc. is recalling HYDROmorphone in dextrose 5% (0.1 mg/mL), 30 mL syringes due to lack of assurance of sterility. The product is a prescription injectable medication used for pain management.
The recall was initiated because the manufacturer cannot assure that the syringes meet sterility standards. This applies to lot numbers 17-275266 (expiration 10/2/2023) and 17-275666 (expiration 10/8/2023). The product is identified by NDC 71286-2013-2.
The affected product was distributed nationwide in the USA. A total of 274 syringes are subject to this recall. Healthcare facilities and patients who have received this medication should contact Central Admixture Pharmacy Services Inc. or their healthcare provider for further instructions. The recalled product should not be used.
The recalled product
- Product
- HYDROmorphone in dextrose 5%, 3 mg/30 mL, (0.1 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2013-2
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Hazard
- sterility-assurance
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot:17-275266
- Exp. 10/2/2023
- 17-275666
- Exp. 10/8/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27